Complementary effect of fibrinogen and rFVIIa on clotting ex vivo in Bernard-Soulier syndrome and combined use during three deliveries

References

• Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005;3:1773–1782
   PubMed Web of Science ®Google Scholar
• Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998;91:4397–4418
   PubMed Web of Science ®Google Scholar
• Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 1975;255:720–722
   PubMed Web of Science ®Google Scholar
• Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham EG, Kadir RA. Bernard Soulier syndrome in pregnancy: A systematic review. Haemophilia 2010;16:584–591
   PubMed Web of Science ®Google Scholar
• Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352
   PubMed Web of Science ®Google Scholar
• Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005;84:816–822
   PubMed Web of Science ®Google Scholar
• Hacihanefioglu A, Tarkun P, Gonullu E. Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard-Soulier syndrome. Thromb Res 2007;120:455–457
   PubMed Web of Science ®Google Scholar
• Tefre KL, Ingerslev J, Sorensen B. Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia 2009;15:281–284
   PubMed Web of Science ®Google Scholar
• Tanaka KA, Taketomi T, Szlam F, Calatzis A, Levy JH. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg 2008;106:732–738
   PubMed Web of Science ®Google Scholar
• Sorensen B, Asvaldsdottir HS, Gudmundsdottir BR, Onundarson PT. The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery. Thromb Res 2009;667:695–700
   Google Scholar
• Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. Br J Haematol 2013;160:228–236
   PubMed Web of Science ®Google Scholar
• Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000;83:634–635
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Balashov D, Shutluko E, Culic SD, Nizamoutdinova E. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: An audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005;11:401–410
   PubMed Web of Science ®Google Scholar
• Holmberg L, Karpman D, Nilsson I, Olofsson T. Bernard-Soulier syndrome Karlstad: Trp 498–>Stop mutation resulting in a truncated glycoprotein Ib alpha that contains part of the transmembranous domain. Br J Haematol 1997;98:57–63
   PubMed Web of Science ®Google Scholar
• Kenny D, Jonsson OG, Morateck PA, Montgomery RR. Naturally occurring mutations in glycoprotein Ibalpha that result in defective ligand binding and synthesis of a truncated protein. Blood 1998;92:175–183
   PubMed Web of Science ®Google Scholar
• Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003;1:551–558
   PubMed Web of Science ®Google Scholar
• Kostopanagiotou G, Siafaka I, Sikiotis C, Smyrniotis V. Anesthetic and perioperative management of a patient with Bernard-Soulier syndrome. J Clin Anesth 2004;16:458–460
   PubMed Web of Science ®Google Scholar
• Thorarinsdottir HR, Sigurbjornsson FT, Hreinsson K, Onundarson PT, Gudbjartsson T, Sigurdsson GH. Effects of fibrinogen concentrate administration during severe hemorrhage. Acta Anaesthesiol Scand 2010;54:1077–1082
   PubMed Web of Science ®Google Scholar
• Palmason R, Vidarsson B, Sigvaldason K, Ingimarsson JP, Gudbjartsson T, Sigurdsson GH, Onundarson PT. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage. Acta Anaesthesiol Scand 2012;56:636–644
   Google Scholar
• Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, et al. Systematic review: Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011;154:529–540
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, Minford A, Mumford AD, Parapia LA, Perry DJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603–633
   PubMed Web of Science ®Google Scholar
• Fenger-Eriksen C, Anker-Moller E, Heslop J, Ingerslev J, Sorensen B. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: Improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 2005;94:324–329
   PubMed Web of Science ®Google Scholar
• Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001;38:6–9
   Google Scholar
• Kiefer TL, Becker RC. Inhibitors of platelet adhesion. Circulation 2009;120:2488–2495
   Google Scholar
• Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003;9:348–352
   PubMed Web of Science ®Google Scholar
• Johansen RF, Sorensen B, Ingerslev J. Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia 2006;12:190–197
   Google Scholar
• Wiinberg B, Jensen AL, Rozanski E, Johansson PI, Kjelgaard-Hansen M, Tranholm M, Kristensen AT. Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs. Vet J 2009;179:121–129
   Google Scholar
• Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008;14:898–902
   PubMed Web of Science ®Google Scholar